RU2753056C2 - Бициклические гетероарильные производные в качестве стимуляторов cftr - Google Patents

Бициклические гетероарильные производные в качестве стимуляторов cftr Download PDF

Info

Publication number
RU2753056C2
RU2753056C2 RU2019120990A RU2019120990A RU2753056C2 RU 2753056 C2 RU2753056 C2 RU 2753056C2 RU 2019120990 A RU2019120990 A RU 2019120990A RU 2019120990 A RU2019120990 A RU 2019120990A RU 2753056 C2 RU2753056 C2 RU 2753056C2
Authority
RU
Russia
Prior art keywords
pyrrolo
trifluoromethyl
pyrimidin
triazine
amino
Prior art date
Application number
RU2019120990A
Other languages
English (en)
Russian (ru)
Other versions
RU2019120990A3 (https=
RU2019120990A (ru
Inventor
Джозеф Уолтер СТРОНБЕЧ
Дэвид Кристофер ЛИМБУРГ
Джон Пол МЭТИАС
Этли ТОРАРЕНСЕН
Джеймс Джон МУССО
Рейджиах Алдрин ДЕННИ
Кристоф Вольфганг ЦАПФ
Иван Викторович Ефремов
Original Assignee
Систик Файбросис Фаундейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Систик Файбросис Фаундейшн filed Critical Систик Файбросис Фаундейшн
Publication of RU2019120990A3 publication Critical patent/RU2019120990A3/ru
Publication of RU2019120990A publication Critical patent/RU2019120990A/ru
Application granted granted Critical
Publication of RU2753056C2 publication Critical patent/RU2753056C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2019120990A 2016-12-16 2017-12-14 Бициклические гетероарильные производные в качестве стимуляторов cftr RU2753056C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662435253P 2016-12-16 2016-12-16
US62/435,253 2016-12-16
PCT/US2017/066317 WO2018112149A1 (en) 2016-12-16 2017-12-14 Bycyclic heteroaryl derivatives as cftr potentiators

Publications (3)

Publication Number Publication Date
RU2019120990A3 RU2019120990A3 (https=) 2021-01-18
RU2019120990A RU2019120990A (ru) 2021-01-18
RU2753056C2 true RU2753056C2 (ru) 2021-08-11

Family

ID=62557188

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019120990A RU2753056C2 (ru) 2016-12-16 2017-12-14 Бициклические гетероарильные производные в качестве стимуляторов cftr

Country Status (10)

Country Link
US (4) US10131670B2 (https=)
EP (1) EP3554506B1 (https=)
JP (1) JP7150721B2 (https=)
CN (1) CN110300589B (https=)
AU (2) AU2017378324B2 (https=)
CA (1) CA3046968A1 (https=)
MX (1) MX391651B (https=)
RU (1) RU2753056C2 (https=)
SG (2) SG10201911076QA (https=)
WO (1) WO2018112149A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI735416B (zh) 2014-10-06 2021-08-11 美商維泰克斯製藥公司 囊腫纖維化症跨膜傳導調節蛋白之調節劑
BR112018009212B1 (pt) 2015-11-25 2022-06-14 Gilead Apollo, Llc Método para controlar patógenos fúngicos agrícolas
PL3380479T3 (pl) 2015-11-25 2023-05-08 Gilead Apollo, Llc Triazolowe inhibitory acc i ich zastosowania
AU2016361412A1 (en) 2015-11-25 2018-05-24 Gilead Apollo, Llc Pyrazole ACC inhibitors and uses thereof
EA201890949A1 (ru) 2015-11-25 2018-12-28 Джилид Аполло, Ллс СЛОЖНОЭФИРНЫЕ ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ И ВАРИАНТЫ ИХ ПРИМЕНЕНИЯ
SI3519401T1 (sl) 2016-09-30 2022-01-31 Vertex Pharmaceuticals Incorporated Modulator regulatorja transmembranske prevodnosti pri cistični fibrozi, farmacevtski sestavki, postopki zdravljenja in proces za izdelavo modulatorja
AU2017362350B2 (en) 2016-11-18 2021-12-23 Cystic Fibrosis Foundation Pyrrolopyrimidines as CFTR potentiators
CN110267948B (zh) 2016-12-09 2023-12-08 弗特克斯药品有限公司 囊性纤维化跨膜传导调控剂的调节剂、药物组合物、治疗方法和制备所述调节剂的方法
AU2018279646B2 (en) 2017-06-08 2023-04-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
MA49631A (fr) 2017-07-17 2020-05-27 Vertex Pharma Méthodes de traitement de la fibrose kystique
TWI799435B (zh) 2017-08-02 2023-04-21 美商維泰克斯製藥公司 製備化合物之製程
US10654829B2 (en) 2017-10-19 2020-05-19 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
KR102716244B1 (ko) 2017-12-08 2024-10-14 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
AU2019222758B2 (en) 2018-02-15 2022-07-07 Vertex Pharmaceuticals Incorporated Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cystic fibrosis, and process for making them
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
TWI848092B (zh) * 2019-04-03 2024-07-11 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白調節劑
AU2020290094B2 (en) * 2019-06-10 2024-01-18 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF, COPD, and bronchiectasis
BR112022000507A2 (pt) 2019-07-15 2022-05-10 Novartis Ag Formulações de (s)-3-amino-6-metóxi-n-(3,3,3-trifluoro-2-hidróxi-2-metilpropil)-5-(trifluorometil)picolinamida
TWI899097B (zh) 2019-08-14 2025-10-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
TWI867024B (zh) 2019-08-14 2024-12-21 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
CA3150162A1 (en) 2019-08-14 2021-02-18 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators
KR20230007369A (ko) * 2020-04-07 2023-01-12 아이테오스 벨지움 에스에이 암의 치료를 위한 ent 저해제로서의 거대환식 다이아민 유도체 및 이와 아데노신 수용체 길항제와의 조합물
IL300413A (en) 2020-08-13 2023-04-01 Vertex Pharma Crystal forms of CFTR modulators
KR20230052954A (ko) 2020-08-20 2023-04-20 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 점액 과다분비를 특징으로 하는 호흡기 질환의 치료 방법
EP4225762A1 (en) 2020-10-07 2023-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
AU2021397294A1 (en) 2020-12-10 2023-07-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CN112876524B (zh) * 2021-01-26 2022-10-28 上海法默生物科技有限公司 一种瑞德西韦中间体的制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005007085A2 (en) * 2003-06-20 2005-01-27 The Regents Of The University Of California Pyrazolo pyrimidine derivatives and methods of use thereof
WO2007079164A2 (en) * 2005-12-29 2007-07-12 Abbott Laboratories Protein kinase inhibitors
RU2331642C2 (ru) * 2002-07-19 2008-08-20 Бристол-Маерс Сквибб Компани Новые ингибиторы киназ
EA201070572A1 (ru) * 2007-11-07 2010-12-30 Фолдркс Фармасьютикалз, Инк. Модуляция транспорта белков
EA019961B1 (ru) * 2006-04-04 2014-07-30 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Антагонисты киназы
EA201400707A1 (ru) * 2011-12-15 2014-11-28 Байер Фарма Акциенгезельшафт Дизамещенные бензотиенил-пирролотриазины и их применение в качестве ингибиторов киназы рфрф
EA025177B1 (ru) * 2010-02-05 2016-11-30 Адверио Фарма Гмбх СТИМУЛЯТОР sGC ИЛИ АКТИВАТОР sGC, ПРИМЕНЯЕМЫЙ ДЛЯ ЛЕЧЕНИЯ КИСТОЗНОГО ФИБРОЗА ОТДЕЛЬНО ИЛИ В КОМБИНАЦИИ С ИНГИБИТОРОМ PDE5

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10135815A1 (de) 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
WO2004100868A2 (en) * 2003-04-23 2004-11-25 Abbott Laboratories Method of treating transplant rejection
WO2007064931A2 (en) 2005-12-02 2007-06-07 Bayer Healthcare Llc Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
CN105431437B (zh) 2013-07-02 2020-03-10 理森制药股份公司 PI3K蛋白激酶抑制剂,特别是δ抑制剂和/或γ抑制剂
AU2017362350B2 (en) * 2016-11-18 2021-12-23 Cystic Fibrosis Foundation Pyrrolopyrimidines as CFTR potentiators

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2331642C2 (ru) * 2002-07-19 2008-08-20 Бристол-Маерс Сквибб Компани Новые ингибиторы киназ
WO2005007085A2 (en) * 2003-06-20 2005-01-27 The Regents Of The University Of California Pyrazolo pyrimidine derivatives and methods of use thereof
WO2007079164A2 (en) * 2005-12-29 2007-07-12 Abbott Laboratories Protein kinase inhibitors
EA019961B1 (ru) * 2006-04-04 2014-07-30 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Антагонисты киназы
EA201070572A1 (ru) * 2007-11-07 2010-12-30 Фолдркс Фармасьютикалз, Инк. Модуляция транспорта белков
EA025177B1 (ru) * 2010-02-05 2016-11-30 Адверио Фарма Гмбх СТИМУЛЯТОР sGC ИЛИ АКТИВАТОР sGC, ПРИМЕНЯЕМЫЙ ДЛЯ ЛЕЧЕНИЯ КИСТОЗНОГО ФИБРОЗА ОТДЕЛЬНО ИЛИ В КОМБИНАЦИИ С ИНГИБИТОРОМ PDE5
EA201400707A1 (ru) * 2011-12-15 2014-11-28 Байер Фарма Акциенгезельшафт Дизамещенные бензотиенил-пирролотриазины и их применение в качестве ингибиторов киназы рфрф

Also Published As

Publication number Publication date
BR112019012335A2 (pt) 2020-03-03
RU2019120990A3 (https=) 2021-01-18
CA3046968A1 (en) 2018-06-21
RU2019120990A (ru) 2021-01-18
US10766904B2 (en) 2020-09-08
SG10201911221RA (en) 2020-02-27
EP3554506A1 (en) 2019-10-23
AU2021277702A1 (en) 2021-12-23
US20190016728A1 (en) 2019-01-17
MX391651B (es) 2025-03-21
US10131670B2 (en) 2018-11-20
SG10201911076QA (en) 2020-01-30
US20180170938A1 (en) 2018-06-21
JP2020502103A (ja) 2020-01-23
AU2017378324B2 (en) 2021-09-02
AU2021277702B2 (en) 2023-11-30
AU2017378324A1 (en) 2019-06-27
EP3554506A4 (en) 2020-06-10
US10377762B2 (en) 2019-08-13
WO2018112149A1 (en) 2018-06-21
EP3554506B1 (en) 2021-04-28
US20190016727A1 (en) 2019-01-17
JP7150721B2 (ja) 2022-10-11
US10208053B2 (en) 2019-02-19
MX2019007135A (es) 2019-11-18
CN110300589B (zh) 2023-03-10
US20190330219A1 (en) 2019-10-31
CN110300589A (zh) 2019-10-01

Similar Documents

Publication Publication Date Title
RU2753056C2 (ru) Бициклические гетероарильные производные в качестве стимуляторов cftr
US12612409B2 (en) Pyrrolopyrimidines as CFTR potentiators
HK40015891B (en) Bycyclic heteroaryl derivatives as cftr potentiators
HK40015891A (en) Bycyclic heteroaryl derivatives as cftr potentiators
BR122024011694A2 (pt) Compostos derivados de heteroarila bicíclica como potenciadores de cftr, composição farmacêutica que compreende os mesmos e uso dos ditos compostos para tratar fibrose cística, asma, bronquiectasia, doença pulmonar obstrutiva crônica, constipação, diabetes mellitus, doença do olho seco, pancreatite, rinossinusite ou síndrome de sjogren
BR112019012335B1 (pt) Compostos derivados de heteroarila bicíclica como potenciadores de cftr, composição farmacêutica que compreende os mesmos e uso dos ditos compostos para tratar fibrose cística, asma, bronquiectasia, doença pulmonar obstrutiva crônica, constipação, diabetes mellitus, doença do olho seco, pancreatite, rinossinusite ou síndrome de sjogren
BR122024011694B1 (pt) Compostos derivados de heteroarila bicíclica como potenciadores de cftr, composição farmacêutica que compreende os mesmos e uso dos ditos compostos para tratar fibrose cística, asma, bronquiectasia, doença pulmonar obstrutiva crônica, constipação, diabetes mellitus, doença do olho seco, pancreatite, rinossinusite ou síndrome de sjogren
HK40014108A (en) Pyrrolopyrimidines as cftr potentiators
HK40014108B (en) Pyrrolopyrimidines as cftr potentiators
BR122022008825B1 (pt) Compostos pirrolopirimidinas potenciadores de cftr, composição farmacêutica que compreende os mesmos e usos terapêuticos dos ditos compostos e composição
BR112019010167B1 (pt) Compostos pirrolopirimidinas potenciadores de cftr

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant